Miller, A. A. , Drummond, G. R. and Sobey, C. G. (2005) Selective inhibition of NADPH-oxidase isoforms as a therapeutic strategy in hypertension. Drug Discovery Today: Therapeutic Strategies, 2(3), pp. 187-192. (doi: 10.1016/j.ddstr.2005.08.002)
Full text not currently available from Enlighten.
Abstract
Hypertension is a major public health challenge because of its high frequency and associated cardiovascular risk. Accumulating evidence suggests that reactive oxygen species derived from NADPH-oxidase play a pivotal role in vascular damage associated with hypertension. The clinical benefits of three of the most prescribed classes of cardiovascular drugs might all indirectly involve inhibition of NADPH-oxidase. Thus, development of inhibitors of vascular isoforms of NADPH-oxidase could have substantial benefit in the treatment of hypertension.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Miller, Dr Alyson |
Authors: | Miller, A. A., Drummond, G. R., and Sobey, C. G. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | Drug Discovery Today: Therapeutic Strategies |
Publisher: | Elsevier |
ISSN: | 1740-6773 |
ISSN (Online): | 1740-6773 |
Published Online: | 29 September 2005 |
University Staff: Request a correction | Enlighten Editors: Update this record